Avidity Biosciences, Inc Cash Flow Conversion Efficiency
Avidity Biosciences, Inc cash flow conversion efficiency. Based on the latest financial reports, Avidity Biosciences, Inc (RNAM) has a cash flow conversion efficiency ratio of -0.101x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-169.77 Million) by net assets ($1.69 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Avidity Biosciences, Inc (2018–2025)
Cash flow conversion efficiency of Avidity Biosciences, Inc from 2018 to 2025. This chart illustrates how Avidity Biosciences, Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View RNAM stock price and chart for real-time trading data and today's change.
Avidity Biosciences, Inc Cash Flow Conversion Ratio Explained
Avidity Biosciences, Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Avidity Biosciences, Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Avidity Biosciences, Inc ranked by their cash flow conversion efficiency. Also see Avidity Biosciences, Inc market cap and net worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Novatek Microelectronics Corp
TW:3034
|
0.096x |
|
REXEL S.A. ADR EO 5
F:E7V0
|
N/A |
|
First Horizon Corporation
NYSE:FHN
|
0.091x |
|
CSPC PHARMACEUT.GR. ADR4
F:CVGU
|
N/A |
|
VAT GROUP AG UNSP.ADR 10
F:19V0
|
N/A |
|
Fuzhou Rockchip Electronics Co Ltd
SHG:603893
|
0.034x |
|
Bangkok Bank PCL
BK:BBL
|
0.014x |
|
Shanghai Electric Group Co Ltd
SHG:601727
|
0.009x |
Annual Cash Flow Conversion Efficiency for Avidity Biosciences, Inc (2018–2025)
The table below shows the annual cash flow conversion efficiency of Avidity Biosciences, Inc from 2018 to 2025. Review cash generation quality of Avidity Biosciences, Inc to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $1.69 Billion | $-650.44 Million | -0.385x | -82.43% |
| 2024-12-31 | $1.42 Billion | $-300.87 Million | -0.211x | +11.20% |
| 2023-12-31 | $500.76 Million | $-119.06 Million | -0.238x | -0.86% |
| 2022-12-31 | $578.08 Million | $-136.27 Million | -0.236x | +5.17% |
| 2021-12-31 | $381.43 Million | $-94.81 Million | -0.249x | -105.08% |
| 2020-12-31 | $306.22 Million | $-37.12 Million | -0.121x | -218.15% |
| 2019-12-31 | $-65.36 Million | $2.49 Million | -0.038x | -116.23% |
| 2018-12-31 | $-41.13 Million | $-9.65 Million | 0.235x | -- |
About Avidity Biosciences, Inc
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics called antibody oligonucleotide conjugates (AOCs). Its AOC platform is designed to combine the specificity of monoclonal antibodies with the precision of RNA therapeutics to target the root cause of diseases previously untreatable with such therapeutics. The company's pipeline has three programs in… Read more